The weekly brief · free to read, free to cite
Colorectal Biomarker Coverage Update Anchors a Quiet Week of Fee Schedule and LCD Activity
Week of August 24–30, 2026
A calm week for reimbursement policy watchers, with the bulk of activity landing on clinical laboratory and physician fee schedule administration rather than new coverage fights. The standout is a national coverage update on non-invasive colorectal cancer biomarker testing, arriving alongside routine quarterly fee schedule maintenance and one contractor-level proposed local coverage determination in oncology molecular diagnostics.
CLV Intelligence™ reviewed 43 publications across all 16 Medicare Administrative Contractor jurisdictions this week. 5 are covered below. Every item links its primary government source.
Lead item
CMS Transmittal R13921NCD: NCD 210.3 Screening for Colorectal Cancer-Non-Invasive Biomarker Tests
- Jurisdiction
- National
- Specialty
- Clinical Laboratory
- Type
- ncd
- Effective
- January 4, 2027
This national coverage determination sets the terms under which non-invasive biomarker screening for colorectal cancer is paid, touching lab and diagnosis coding directly and giving labs and ordering clinicians a defined runway before the change takes hold.
Codes:G0464G0532Z12.11
Item 2
CMS Transmittal R13929CP: Quarterly Update to the Medicare Physician Fee Schedule Database (MPFSDB) - October 2026 Update…
- Jurisdiction
- National
- Specialty
- Physician Fee Schedule
- Type
- fee_schedule
- Effective
- October 5, 2026
Quarterly physician fee schedule database refreshes ripple through claims systems nationally regardless of specialty, and the compressed runway before implementation means downstream billing configurations feel it quickly.
Item 3
CMS Transmittal R13884CP: October 2026 Quarterly Update to the Clinical Laboratory Fee Schedule (CLFS) and Clinical…
- Jurisdiction
- National
- Specialty
- Clinical Laboratory
- Type
- fee_schedule
- Effective
- October 5, 2026
This update touches HCPCS coding, waived test status, and reasonable charge payments under the clinical laboratory fee schedule, a trio of levers that together shape what independent and hospital labs collect on covered tests.
Item 4
CMS Transmittal R13921CP: NCD 210.3 Screening for Colorectal Cancer-Non-Invasive Biomarker Tests
- Jurisdiction
- National
- Specialty
- Clinical Laboratory
- Type
- ncd
- Effective
- January 4, 2027
This companion transmittal carries the same colorectal cancer biomarker coverage policy into the claims-processing manual, meaning the operational billing mechanics arrive on the same timeline as the coverage determination itself.
Item 5
Proposed LCD DL40431: MolDX: Genome-Wide Molecular Methodologies for the Detection of Copy Number Alterations and Structural Variants in Hematologic Neoplasms — CGS
- Jurisdiction
- CGS Administrators
- Specialty
- Oncology
- Type
- lcd
- Effective
- Not announced
A proposed local coverage determination from a single Midwest-jurisdiction contractor would set medical necessity criteria for genome-wide molecular testing in blood cancers, reaching pathology and oncology labs that run copy number and structural variant panels ahead of any final policy.
Codes:8130181403814558147988271C83.30C90.00C91.10C92.00D46.9
Five items, one active MAC jurisdiction, and a modest set of affected codes describe a week of routine maintenance punctuated by one substantive coverage decision — worth tracking rather than reacting to.
See what changed in your jurisdiction
This brief covers the week. The free 90-day snapshot covers your specialty and your MAC — every policy change on record, with its source.
CLV Intelligence monitors and summarizes publicly available federal and MAC publications. It is not legal, medical, billing, or coding advice.